期刊文献+

子宫内膜异位症患者异位及在位内膜组织中BCAR1的表达及其意义 被引量:5

Expression and significance of BCAR1 in ectopic endometrium and eutopic endometrium in patients with endometriosisy
下载PDF
导出
摘要 目的观察子宫内膜异位症(EMS)患者异位和在位内膜组织中抗雌激素药物耐药性基因1(BCAR1)表达,并分析其临床意义。方法选取2016年2月至2016年12月在浙江省乐清市人民医院接受治疗的100例EMS患者为研究对象(EMS组),同时选取同期在浙江省乐清市人民医院接受体检筛查的100例健康成年人作为对照组。观察两组内膜组织中BCAR1的表达和血管内皮生长因子(VEGF)、肿瘤坏死因子-α(TNF-α)、白介素-1β(IL-1β)、癌抗原125(CA125)水平,比较EMS患者异位内膜及在位内膜组织中BCAR1的差异,分析子宫内膜异位症患者BCAR1表达与VEGF、TNF-α、IL-1β、CA125水平的相关性。结果 EMS组患者组织中的BCAR1阳性表达率为85.00%,明显高于对照组(χ~2=106.676,P<0.001);EMS组患者血清VEGF、TNF-α、IL-1β、CA125水平分别为228.72±12.35ng/L、46.33±5.96pg/mL、165.82±13.02ng/L、332.46±12.13U/mL,明显高于对照组(t值分别为-39.764、-41.339、-24.083、-97.792,均P<0.001);EMS患者异位内膜中BCAR1阳性表达率为95.0%,明显高于在位内膜中BCAR1阳性表达率(χ~2=15.686,P<0.001);子宫内膜异位症患者BCAR1阳性表达率与血清VEGF、TNF-α、IL-1β、CA125水平明显正相关(r值分别为0.587、0.612、0.542、0.598,均P<0.05)。结论 EMS患者的异位内膜组织中BCAR1阳性表达率较高,且与患者血清VEGF、TNF-α、IL-1β、CA125水平正相关,可作为临床监测的重要指标。 Objective To investigate the expression of breast cancer anti-estrogen resistance 1(BCAR1)in ectopic endometrium and eutopic endometrium in patients with endometriosis(EMS)and to analyze its clinical significance.Methods 100 EMS patients treated in Yueqing Municipal People's Hospital of Zhejiang Province from February to December in 2016 were selected as subjects,and healthy adults who underwent physical examination in the hospital were selected as controls.Expression of BCAR1 and levels of vascular endothelial growth factor(VEGF),tumor necrosis factor alpha(TNF-α),interleukin-1β(IL-1β),and cancer antigen125(CA125)were observed in two groups.BCAR1 was compared between ectopic endometrium and eutopic endometrial in EMS patients,and analysis was conducted on correlation of BCAR1 expression in patients with EMS and levels of VEGF,TNF-α,IL-1βand CA125.Results Positive expression rate of BCAR1 in eutopic endometrium of EMS group was 85.00%,which was significantly higher than that of the control group(χ~2=106.676,P0.001).Levels of serum VEGF,TNF-α,IL-1βand CA125 in EMS group of patients were 228.72±12.35 ng/L,46.33±5.96 Pg/ml,165.82±13.02 ng/L,332.46±12.13 U/ml,respectively,which were significantly higher than those in the control group(t value was-39.764,-41.339,-24.083 and-97.792,respectively,all P0.001).Positive expression rate of BCAR1 was 95.0%in EMS patients with ectopic endometrium,and it was significantly higher than that in eutopic endometrium(χ~2=15.686,P 0.001).A significant positive correlation was found between positive expression rate of BCAR1 and serum levels of VEGF,TNF-α,IL-1βand CA125(r value was 0.587,0.612,0.542 and 0.598,respectively,all P〈0.05).Conclusion Positive expression rate of BCAR1 in ectopic endometrium of EMS patients is relatively high,and it is positively corralted with the serum levels of VEGF,TNF-α,IL-1βand CA125.So it can be used as an important index for clinical monitoring.
作者 何海美 潘晔
出处 《中国妇幼健康研究》 2017年第11期1418-1421,共4页 Chinese Journal of Woman and Child Health Research
关键词 子宫内膜异位症 雌激素 血管生长因子 炎症因子 抗雌激素药物耐药性基因1 endometriosis-(EMS) estrogen vascular growth factor (VGF) inflammatory factor breast cancer anti-estrogenresistance 1 (BCAR1)
  • 相关文献

参考文献6

二级参考文献153

  • 1易俊林,柴微田,平岡真宽.RNA干扰技术失活Rad51基因增加肿瘤细胞放射敏感性的研究[J].中华放射肿瘤学杂志,2006,15(6):473-476. 被引量:3
  • 2邢长英,归绥琪.SOCS3作用机制与妇产科研究进展[J].生殖与避孕,2007,27(4):287-291. 被引量:5
  • 3Afshar Y,Hastings J,Roqueiro D,et al. Changes in eutopic endometrial gene expression during the progres- sion of experimentalendometriosis in the baboon, papio Anubis[J]. Biol Reprod,2013,88(2) .44.
  • 4Pabona JM, Simmen FA, Nikiforov MA, et al. Krappel- like factor 9 and progesterone receptor coregulation of decidualizing endometrial stromal cells: implications for the pathogenesis of endometriosis[J]. J Clin Endocrinol Metab,2012,97(3) :E376- 392.
  • 5Miki Y. SwensenJ. Shattuck- Eidens D. et al. A strong candi- date for the breast and ovarian cancer susceptibility gene BRCAI[J]. Science. 1994. 266(5182) :66-7l.
  • 6Moran A. O'Hara C. Khan S. et al. Risk of cancer other than breast or ovarian in individuals with BRCAI and BRCA2 mutations[J]. Fam Cancer. 2012.11(2) :235-242.
  • 7Alanee SR. Glogowski EA. Schrader KA. et al. Clinical features and management of BRCAI and BRCA2-associated prostate cancer] I}. Front Biosci (Elite Ed). 2014.6: 15-30.
  • 8Garg K. Levine DA. Olvera N. et al. BRCAI immunohistochemistry in a molecularly characterized cohort of ovarian highgrade serous carcinomas[J]. AmJ Surg Pathol , 2013. 37 (1): 138-46.
  • 9Lan YT,Jen-Kou L. Lin CH, et al. Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers[J].J Surg On col , 2015, 111(7) :905-910.
  • 10Segev Y. IqbalJ. LubinskiJ. et al. Hereditary Breast Cancer Study Group. The incidence of endometrial cancer in women with BRCAI and BRCA2 mutations: an international prospective cohort study[J]. Gynecol Oncol , 2013.1300) :127-131.

共引文献103

同被引文献40

引证文献5

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部